Biogen stock heads for its worst single-day drop since July 2024 on the heels of new clinical data.
Biogen said signals suggest the treatment decreases levels of tau and slows cognitive decline, particularly at the lowest ...
The FDA has approved Auvelity as the first non-antipsychotic treatment for agitation in Alzheimer's disease, marking a major ...
Biogen (BIIB.O), opens new tab said on Thursday its Alzheimer’s drug did not meet the main goal of a mid-stage ...
Biogen Inc. said it will continue development of its experimental Alzheimer’s drug after getting promising though not ...
One of the company’s more closely watched research assets, BIIB080 is now heading to late-stage testing based on “the ...
Eli Lilly has launched Lormalzi (donanemab) in India for early Alzheimer's disease at Rs91,688 per vial. The once-monthly ...
An existing drug for HIV could double as a preventative therapy for Alzheimer’s disease, according to researchers. NRTIs (nucleoside reverse transcriptase inhibitors) are antivirals that are approved ...
Alzheimer’s disease remains one of medicine’s toughest challenges, affecting millions and costing trillions of dollars annually. If someone you know has Alzheimer’s, you’ve likely experienced ...
Biogen shares are down nearly 3% after the company’s experimental drug for Alzheimer's disease failed to meet its main goal of showing that higher doses produced greater benefits for patients. The ...
From the subtle differences between memory lapses and brain disease to the lifestyle changes that can lower your risk, Dr Tim Beanland at Alzheimer’s Society helps you navigate the facts about dementi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results